-
公开(公告)号：US20240139234A1
公开(公告)日：2024-05-02
申请号：US18260067
申请日：2021-11-04
发明人： Min FU , Minglong HU , Tongtong LI , Ying LIANG , Xiaolong WANG , Yao YU , Faming ZHANG
IPC分类号： A61K31/78 , A61P3/00 , C08F220/22
CPC分类号： A61K31/78 , A61P3/00 , C08F220/22
摘要： Provided herein is a potassium-binding polymer prepared by polymerization reaction of a monomer and a crosslinking agent, wherein the monomer is the compound of formula (V), the crosslinking agent is the compound of formula (VI), and/or the compound of formula (VII), wherein the variables are as defined in the specification; to the use thereof for treating or preventing hyperkalemia.
-
2.发明授权公开(公告)号：US11690869B2
公开(公告)日：2023-07-04
申请号：US16856766
申请日：2020-04-23
发明人： Elizabeth Bruning , Kimberly Capone , Lisa Renee Gandolfi , Anthony Robert Geonnotti, III , Euen Thomas Ekman-Gunn , Diana Roshek Johnson , Frank J. Kirchner , Selina Moses , Delores Santora , Russel Walters , Frank C. Sun
IPC分类号： A61K31/78
CPC分类号： A61K31/78
摘要： This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a low molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses, wherein said compositions further comprise less than about 9% by weight of surfactant having an HLB of greater than 12.
-
公开(公告)号：US11564918B2
公开(公告)日：2023-01-31
申请号：US16340812
申请日：2017-10-10
发明人： Gerard P. Frunzi , Sibao Chen , Rajeev A. Jain
摘要： Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.
-
公开(公告)号：US20230025693A1
公开(公告)日：2023-01-26
申请号：US17811972
申请日：2022-07-12
申请人： Avicanna Inc.
IPC分类号： A61K36/185 , A61K31/25 , A61K31/047 , A61K9/06 , A61K31/717 , A61K31/78
摘要： Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein to the skin areas of a subject affected by inflammation and/or pain associated with musculoskeletal disease or condition and uses of a topical cannabinoid formulation provided herein for the treatment of inflammation and/or pain associated with musculoskeletal disease or condition in a subject.
-
公开(公告)号：US20220409654A1
公开(公告)日：2022-12-29
申请号：US17770536
申请日：2020-10-22
发明人： Carlo Terruzzi
IPC分类号： A61K31/728 , A61K36/899 , A61K31/77 , A61K31/78 , A61K31/401 , A61K31/198 , A61K9/16 , A61K9/06 , A61K9/00 , A61P1/04 , A61P17/02
摘要： The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: carbomer (poly acrylic acid) in the range from 0.05% to 5%; sodium hyaluronate in the range from 0.01% to 15%; poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; Oryza sativa extract in the range from 0.2% to 20%; and one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).
-
公开(公告)号：US20220226365A1
公开(公告)日：2022-07-21
申请号：US17611999
申请日：2020-05-15
发明人： Diana Hoejberg
摘要： The present invention relates to photopolymerizable acrylate-based compositions for producing a light-curing lacquer for the therapy of onychomycosis or of a bacterial nail infection for a human or animal toenail or fingernail, the compositions being devoid of a classic antimycotic active ingredient. Various different acrylates can be used to produce the claimed compositions.
-
公开(公告)号：US20220218738A1
公开(公告)日：2022-07-14
申请号：US17593127
申请日：2020-03-12
申请人： AstraZeneca AB
发明人： Jenny JONASSON , Nicolas GUZMAN
摘要： The present invention relates to the use of potassium-binding agents that are formulated to remove toxins, e.g., potassium ions, from the gastrointestinal tract at an elevated rate, without causing undesirable side effects, in hemodialysis patients. The compositions exhibit desired characteristics for the long term administration to treat or prevent the relapse or occurrence of certain conditions, for example hyperkalemia.
-
公开(公告)号：US11331340B2
公开(公告)日：2022-05-17
申请号：US16806936
申请日：2020-03-02
申请人： MicroVention, Inc.
摘要： Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.
-
公开(公告)号：US11324707B2
公开(公告)日：2022-05-10
申请号：US16869309
申请日：2020-05-07
发明人： Derek Moe , Randal Seburg , Sagar Rane
IPC分类号： A61K31/135 , A61K9/16 , A61K9/00 , A61K31/78 , A61K33/10
摘要： Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.
-
公开(公告)号：US11219639B2
公开(公告)日：2022-01-11
申请号：US15746810
申请日：2016-07-22
申请人： Trimph IP Pty Ltd
发明人： Ali Fathi , Fariba Dehghani
IPC分类号： A61K31/60 , C08F220/54 , C07C65/10 , C08F220/56 , C08L33/26 , A61K31/78 , A61K47/58 , A61K47/59 , A61K47/61 , A61K47/69 , A61K47/60 , A61L27/16 , A61L27/52 , A61L27/54 , A61L27/58
摘要： According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein: the water-soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy-ethyl-methyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N-acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N-isopropyl acrylamide (NIPAAm) moiety. The anti-septic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).
-
-
-
-
-
-
-
-
-
搜索结果
616 条记录 (耗时 0.061 秒)
